Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Electromed ( (ELMD) ) has issued an update.
On September 9, 2025, Electromed, Inc. announced a new share repurchase authorization of up to $10 million following the exhaustion of its previous authorization. The decision, driven by strong operational performance and robust cash reserves, aims to enhance shareholder value, with repurchases dependent on market conditions and corporate considerations.
The most recent analyst rating on (ELMD) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Electromed stock, see the ELMD Stock Forecast page.
Spark’s Take on ELMD Stock
According to Spark, TipRanks’ AI Analyst, ELMD is a Outperform.
Electromed’s strong financial performance and positive earnings call outlook are somewhat offset by bearish technical signals and a moderate valuation. The company’s consistent revenue growth and profitability are significant strengths, but technical analysis indicates potential short-term challenges.
To see Spark’s full report on ELMD stock, click here.
More about Electromed
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992.
Average Trading Volume: 82,663
Technical Sentiment Signal: Strong Buy
Current Market Cap: $204.3M
See more data about ELMD stock on TipRanks’ Stock Analysis page.